It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Lenvima Gets China OK for 1st Line HCC: Eisai/Merck
September 6, 2018
- I/O in Lung Cancer - 4: Bristol-Myers Looks to Regain Ground for Opdivo with Immunotherapy Combos
September 5, 2018
- FDA Snubs Sunovion’s ADHD Drug
September 4, 2018
- Life Science Institute to Initiate Exploratory Clinical Study of Muse Cell Product for Cerebral Infarction
September 4, 2018
- Thrombocytopenia Drug Mulpleta Now Available in US: Shionogi
September 3, 2018
- Yamaha Motor to Invest in Biotech Evec to Strengthen Presence in Biomedical Field
September 3, 2018
- Taisho’s Voluntary Early Retirement Program Attracts 948 Applicants
September 3, 2018
- Kowa’s Parmodia Most Heavily Pitched for GPs in June: Anterio
August 31, 2018
- Global Biologic Market Rises 13.9% to 18.6 Trillion Yen in FY2017 Driven by I/O Drugs
August 31, 2018
- With Bullish Maviret, AbbVie Aims for Double-Digit Growth to Join Top 20 in 2018
August 30, 2018
- South Korea OKs Lenvima for 1st Line HCC: Eisai
August 30, 2018
- Eisai/Biogen’s Alzheimer’s Drug Aducanumab Shows Continued Efficacy in Long-Term Extension PIb Study
August 30, 2018
- Imfinzi, Gazyva Now Available in Japan
August 30, 2018
- Celltrion Launches Herceptin Biosimilar in Japan
August 29, 2018
- Ono Hooks Up with BMS, Clovis to Develop Opdivo/Rucaparib Combo Therapy in Japan, S. Korea, Taiwan
August 29, 2018
- I/O in Lung Cancer - 3: Pfizer Sets Sights on Ovarian Cancer after NSCLC Trial Fails
August 28, 2018
- Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
- New AG Re-Pricing Rule Erodes 10 Billion Yen from Daiichi Sankyo Espha Sales
August 28, 2018
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
- Opdivo Price Cut Won’t Have Much Impact on Financial Results: Ono
August 27, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…